Medindia

X

Perrigo Acquires UK OTC Store Brand Supplier

Thursday, January 10, 2008 General News J E 4
Advertisement
ALLEGAN, Mich., Jan. 9 Perrigo Company(Nasdaq: PRGO; TASE) today announced that it has acquired Galpharm Healthcare,Ltd. for $86 million in cash. Based in Barnsley, Yorkshire, United Kingdom,privately-held Galpharm is a leading supplier of over-the-counter (OTC) storebrand pharmaceutical products sold by super markets, drug stores andpharmacies in the U.K. The acquisition is expected to add more than $55million in sales annually and be accretive to earnings in the first year.

Perrigo Chairman and CEO Joseph C. Papa stated, "The acquisition ofGalpharm further expands our global presence, complements our existing UKbusiness and increases value for our shareholders. It also helps us meet theworld's growing need for quality, affordable healthcare."

Perrigo Company is a leading global healthcare supplier that develops,manufactures and distributes over-the-counter (OTC) and prescriptionpharmaceuticals, nutritional products, active pharmaceutical ingredients (API)and consumer products. The Company is the world's largest manufacturer of OTCpharmaceutical products for the store brand market. The Company's primarymarkets and locations of manufacturing facilities are the United States,Israel, Mexico and the United Kingdom. Visit Perrigo on the Internet(http://www.perrigo.com).

Note: Certain statements in this press release are forward-lookingstatements within the meaning of Section 21E of the Securities Exchange Act of1934, as amended, and are subject to the safe harbor created thereby. Thesestatements relate to future events or the Company's future financialperformance and involve known and unknown risks, uncertainties and otherfactors that may cause the actual results, levels of activity, performance orachievements of the Company or its industry to be materially different fromthose expressed or implied by any forward-looking statements. In some cases,forward-looking statements can be identified by terminology such as "may,""will," "could," "would," "should," "expect," "plan," "anticipate," "intend,""believe," "estimate," "predict," "potential" or other comparable terminology.The Company has based these forward-looking statements on its currentexpectations, assumptions, estimates and projections. While the Companybelieves these expectations, assumptions, estimates and projections arereasonable, such forward-looking statements are only predictions and involveknown and unknown risks and uncertainties, many of which are beyond theCompany's control. These and other important factors, including thosediscussed under "Risk Factors" in the Company's Form 10-K for the year endedJune 30, 2007, as well as the Company's subsequent filings with the Securitiesand Exchange Commission, may cause actual results, performance or achievementsto differ materially from those expressed or implied by these forward-lookingstatements. The forward-looking statements in this press release are madeonly as of the date hereof, and unless otherwise required by applicablesecurities laws, the Company disclaims any intention or obligation to updateor revise any forward-looking statements, whether as a result of newinformation, future events or otherwise.

SOURCE Perrigo Company
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
ExonHit and bioMerieux Amend Their Strategic Partn...
S
Prominent Respiratory Therapist and Author Joins S...